Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: Effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection

Journal of Virology

Volumn 88, Issue 8, 2014, Pages 4237-4250

  Liang, Bo ^a   Munir, Shirin ^a   Amaro Carambot, Emerito ^a   Surman, Sonja ^a   Mackow, Natalie ^a   Yang, Lijuan ^a   Buchholz, Ursula J ^a   Collins, Peter L ^a   Schaap Nutt, Anne ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MESSENGER RNA; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS FUSION F GLYCOPROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA FLANKING REGION; DRUG DESIGN; GENE INSERTION; GENETIC STABILITY; HAMSTER; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PARAINFLUENZA VIRUS 3; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; SYNCYTIUM; TEMPERATURE SENSITIVITY; VACCINATION; VACCINE PRODUCTION; VERO CELL; VIRUS GENOME; VIRUS PLAQUE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; GENETIC VECTORS; HUMANS; MESOCRICETUS; PARAINFLUENZA VIRUS 3, BOVINE; PARAINFLUENZA VIRUS 3, HUMAN; PROTEIN ENGINEERING; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 84896918365     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03481-13     Document Type: Article

References (53)

1. Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim H-W, Brandt CD, Chanock RM. 1988. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 11:1-15. http://dx.doi.org/10.1016/0168-1702(88)90063-9, http://dx.doi.org/10.1016/0 168-1702(88)90099-8.
2. Schmidt A, Schaap Nutt A, Bartlett E, Schomacker H, Boonyaratanakornkit J, Karron R, Collins P. 2011. Progress in the development of human parainfluenza virus vaccines. Expert Rev. Respir. Med. 5:515-526. http://dx.doi.org/10.1586/ers.11.32.
3. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. 1997. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children >5 years old. J. Infect. Dis. 175:807-813. http://dx.doi.org/10.1086/513975.
4. Nair H, Nokes DJ, Gessner B, Dherani M, Madhi S, Singleton R, O'Brien K, Roca A, Wright P, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih E, Ngama M, Munywoki P, Kartasasmita C, Simões EAF, Rudan I, Weber M, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
5. Weinberg G, Hall C, Iwane M, Poehling K, Edwards K, Griffin M, Staat M, Curns A, Erdman D, Szilagyi P. 2009. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J. Pediatr. 154:694-699. http://dx.doi.org/10.1016/j.jpeds.2008.11.034.
6. Hall C, Weinberg G, Iwane M, Blumkin A, Edwards K, Staat M, Auinger P, Griffin M, Poehling K, Erdman D, Grijalva C, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360:588-598. http://dx.doi.org/10.1056/NEJMoa0804877.
7. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
8. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484. http://dx.doi.org/10.1016/0264-410X(92)90397-3.
9. Ottolini MG, Porter DD, Hemming VG, Prince GA. 2000. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol. 13:231-236. http://dx.doi.org/10.1089/vim.2000.13.231.
10. Yim KC, Cragin RP, Boukhvalova MS, Blanco JC, Hamlin ME, Boivin G, Porter DD, Prince GA. 2007. Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 25:5034-5040. http://dx.doi.org/10.1016/j.vaccine.2007.04.075.
11. Hamelin ME, Couture C, Sackett MK, Boivin G. 2007. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J. Gen. Virol. 88:3391-3400. http://dx.doi.org/10.1099/vir.0.83250-0.
12. Bernstein D, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. 2012. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr. Infect. Dis. J. 31:109-114. http://dx.doi.org/10.1097/INF.0b013e31823386f1.
13. Wright P, Karron R, Belshe R, Shi J, Randolph V, Collins P, O'Shea A, Gruber W, Murphy B. 2007. The absence of enhanced disease with wildtype respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25:7372-7378. http://dx.doi.org/10.1016/j.vaccine.2007.08.014.
14. Belshe R, Newman F, Tsai T, Karron R, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson F, Rodriguez W, Severs J, Wright P, Keyserling H, Weinberg G, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler J, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu S-L, Tatem J, Murphy B, Anderson E. 2004. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J. Infect. Dis. 189:462-470. http://dx.doi.org/10.1086/381184.
15. Hurwitz JL. 2011. Respiratory syncytial virus vaccine development. Expert Rev. Vaccines 10:1415-1433. http://dx.doi.org/10.1586/erv.11.120.
16. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
17. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. 2001. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75:4594-4603. http://dx.doi.org/10.1128/JVI.75.10.4594-4603.2001.
18. Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, Collins PL, Murphy BR, Skiadopoulos MH. 2000. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J. Virol. 74:8922-8929. http://dx.doi.org/10.1128/JVI.74.19.8922-8929.2000.
19. Tang R, Schickli J, MacPhail M, Fernandes F, Bicha L, Spaete J, Fouchier RAM, Osterhaus ADME, Spaete R, Haller A. 2003. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J. Virol. 77:10819-10828. http://dx.doi.org/10.1128/JVI.77.20.10819-10828.2003.
20. Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC. 2012. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 30:3975-3981. http://dx.doi.org/10.1016/j.vaccine.2011.12.022.
21. Gomez M, Mufson M, Dubovsky F, Knightly C, Zeng W, Losonsky G. 2009. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr. Infect. Dis. J. 28:655-658. http://dx.doi.org/10.1097/INF.0b013e318199c3b1.
22. Yang C-F, Wang CK, Malkin E, Schickli JH, Shambaugh C, Zuo F, Galinski MS, Dubovsky F, Tang RS. 2013. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine 31:2822-2827. http://dx.doi.org/10.1016/j.vaccine.2013.04.006.
23. Conzelmann KK. 1998. Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annu. Rev. Genet. 32:123-162. http://dx.doi.org/10.1146/annurev.genet.32.1.123.
24. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, García-Sastre A. 2009. Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 83:584-597. http://dx.doi.org/10.1128/JVI.01443-08.
25. Tao T, Skiadopoulos MH, Davoodi F, Riggs JM, Collins PL, Murphy BR. 2000. Replacement of the ectodomains of the hemagglutininneuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J. Virol. 74:6448-6458. http://dx.doi.org/10.1128/JVI.74.14.6448-6458.2000.
26. Quiñones-Kochs MI, Schnell MJ, Buonocore L, Rose JK. 2001. Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology 287:427-435. http://dx.doi.org/10.1006/viro.2001.1058.
27. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2013. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, liveattenuated vaccine candidate that is phenotypically stable at physiological temperature. J. Virol. 87:1985-1996. http://dx.doi.org/10.1128/JVI.02769-12.
28. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elon-gation factor from the 5' proximal open reading frame of the M2mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. U. S. A. 92:11563-11567. http://dx.doi.org/10.1073/pnas.92.25.11563.
29. Hall SL, Stokes A, Tierney EL, London WT, Belshe RB, Newman FC, Murphy BR. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:173-184. http://dx.doi.org/10.1016/0168-1702(92)90049-F.
30. Calain P, Roux L. 1993. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 67:4822-4830.
31. Kolakofsky D, Pelet T, Garcin D, Hausmann S, Curran J, Roux L. 1998. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J. Virol. 72:891-899.
32. Buchholz UJ, Finke S, Conzelmann K-K. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73:251-259.
33. Clemons DJ, Besch Williford C, Steffen EK, Riley LK, Moore DH. 1992. Evaluation of a subcutaneously implanted chamber for antibody production in rabbits. Laboratory 42:307-311.
34. Beeler JA, van Wyke Coelingh K. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63:2941-2950.
35. Coates HV, Alling DW, Chanock RM. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:299-313.
36. van Wyke Coelingh KL, Winter CC, Tierney EL, London WT, Murphy BR. 1988. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J. Infect. Dis. 157:655-662. http://dx.doi.org/10.1093/infdis/157.4.655.
37. Durbin AP, Cho CJ, Elkins WR, Wyatt LS, Moss B, Murphy BR. 1999. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J. Infect. Dis. 179:1345-1351. http://dx.doi.org/10.1086/314769.
38. Coates HV, Forsyth BR, Chanock RM. 1966. Biophysical studies of respiratory syncytial virus. I. Density of respiratory syncytial virus and associated complement-fixing antigens in cesium chloride density gradient. J. Bacteriol. 91:1263-1269.
39. Collins PL, Karron RA. 2013. Respiratory syncytial virus and metapneumovirus, p 1086-1123. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott/The Williams & Wilkins Co, Philadelphia, PA.
40. Haller AA, Miller T, Mitiku M, Coelingh K. 2000. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J. Virol. 74:11626-11635. http://dx.doi.org/10.1128/JVI.74.24.11626-11635.2000.
41. Suspène R, Petit V, Puyraimond-Zemmour D, Aynaud M-M, Henry M, Guétard D, Rusniok C, Wain-Hobson S, Vartanian J-P. 2011. Doublestranded RNA adenosine deaminase ADAR-1-induced hypermutated genomes among inactivated seasonal influenza and live attenuated measles virus vaccines. J. Virol. 85:2458-2462. http://dx.doi.org/10.1128/JVI.02138-10.
42. Lawrence MC, Borg NA, Streltsov VA, Pilling PA, Epa VC, Varghese JN, McKimm-Breschkin JL, Colman PM. 2004. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J. Mol. Biol. 335:1343-1357. http://dx.doi.org/10.1016/j.jmb.2003.11.032.
43. Mason JN, Elbahesh H, Russell CJ. 2013. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines. J. Virol. 87:5959-5969. http://dx.doi.org/10.1128/JVI.00227-13.
44. Burke CW, Mason JN, Surman SL, Jones BG, Dalloneau E, Hurwitz JL, Russell CJ. 2011. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. 7:e1002134. http://dx.doi.org/10.1371/journal.ppat.1002134.
45. Tokusumi T, Iida A, Hirata T, Kato A, Nagai Y, Hasegawa M. 2002. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res. 86:33-38. http://dx.doi.org/10.1016/S0168-1702 (02)00047-3.
46. Nelson CL, Tang RS, Stillman EA. 2013. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells. Vaccine 31:3756-3762. http://dx.doi.org/10.1016/j.vaccine.2013.04.015.
47. Moscona A, Peluso RW. 1993. Relative affinity of the human parainfluenza virus type 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity. J. Virol. 67:6463-6468.
48. Porotto M, Fornabaio M, Kellogg GE, Moscona A. 2007. A second receptor binding site on human parainfluenza virus type 3 hemagglutininneuraminidase contributes to activation of the fusion mechanism. J. Virol. 81:3216-3228. http://dx.doi.org/10.1128/JVI.02617-06.
49. Palermo LM, Porotto M, Yokoyama CC, Palmer SG, Mungall BA, Greengard O, Niewiesk S, Moscona A. 2009. Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. J. Virol. 83: 6900-6908. http://dx.doi.org/10.1128/JVI.00475-09.
50. Porotto M, Palmer SG, Palermo LM, Moscona A. 2012. Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry. J. Biol. Chem. 287:778-793. http://dx.doi.org/10.1074/jbc. M111.298059.
51. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2012. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J. Virol. 86:10792-10804. http://dx.doi.org/10.1128/JVI.01227-12.
52. Durbin AP, McAuliffe JM, Collins PL, Murphy BR. 1999. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 261:319-330. http://dx.doi.org/10.1006/viro.1999.9878.
53. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612. http://dx.doi.org/10.1002/jcc.20084.